Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOCIACS
2023-505109-17-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute chest syndrome (ACS) and sickle cell disease (SCD) comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Time to successful weaning from supplemental oxygen and respiratory support. Planned start Oct 2024; status: authorised.
02
Drugs
tocilizumab
03
Conditions
acute chest syndrome (ACS)sickle cell disease (SCD)
Beyond the preview
Go deeper on 2023-505109-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505109-17-00.